COR · Full Picture

Cencora, Inc. — the full picture

Earnings window · 2026-07-15 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Outstanding Indebtedness · Debt, leverage & refinancingPriority 83
    -23.0% liability (realized); structured_verified
    The increase in interest expense was primarily due to the issuance of $3.0 billion of senior notes and $1.5 billion of variable-rate term loans in February 2026 borrowed to finance a portion of the OneOncology acquisition.
  2. Guidance and Outlook · Guidance & outlookPriority 80
    +9.5% revenue; 2 sources (news, press_release); 4 forward row(s); quote_verified
    Cencora expects fiscal 2026 revenue growth of 4% to 6% (2026 Guidance) versus fiscal 2025 actuals $321.3B
  3. Revenue Performance and Mix · Revenue growth & mixPriority 77
    +33.2% revenue (realized); 3 sources (news, press_release, sec_filing); structured_verified
    Revenue for the third quarter of fiscal 2026: $84.8 billion, a 5.1 percent increase year-over-year
  4. Acquisitions and Divestitures · M&A and divestituresPriority 72
    -5.5% cash (realized); 3 sources (news, press_release, sec_filing); 1 forward row(s); structured_verified
    We recorded a $1.1 billion gain on the remeasurement of our equity method investment and the extinguishment of the put option liability related to our previously held investment in OneOncology in other income, net in the nine months ended June 30, 2026.
  5. Gross Margin Drivers · Gross marginPriority 67
    +5.7% operating_income (realized); 3 sources (news, press_release, sec_filing); structured_verified
    LIFO credit was $94.3 million for the three months ended June 30, 2026 and $52.1 million for the three months ended June 30, 2025; LIFO credit was $381.9 million for the nine months ended June 30, 2026 and $19.9 million for the nine months ended June 30, 2025.
  6. Liquidity and Debt Position · Debt, leverage & refinancingPriority 65
    -5.4% liability (realized); 2 sources (news, press_release); quote_verified
    In the nine months ended June 30, 2026 financing activities included issuance of $3.0 billion of senior notes and $1.5 billion of term loans to finance a portion of the February 2, 2026 acquisition of OneOncology
  7. GLP-1 Product Demand · Demand, orders & backlogPriority 62
    +8.8% revenue (realized); quote_verified
    Sales of products labeled for diabetes and/or weight loss in the GLP-1 class increased by $2.3 billion, or 25.5%, from the prior year quarter and by $5.2 billion, or 19.7%, from the prior year nine-month period.
  8. Liquidity and Debt Position · UnclassifiedPriority 60
    -2.8% liability; 1 forward row(s); quote_verified
    We had a $5.5 billion Multi-Currency Revolving Credit Facility scheduled to expire in June 2030 which in July 2026 was amended and restated to extend expiration to July 2031 and increase commitments to $7.0 billion.
  9. Market Demand Trends · Demand, orders & backlogPriority 60
    3 sources (news, press_release, sec_filing); quote_verified
    Reports attribute the quarter's outperformance to strong demand for specialty medicines and specialty-business momentum.
  10. Capital Return Program · Buybacks & dividendsPriority 57
    +1.6% cash (realized); 3 sources (news, press_release, sec_filing); 1 forward row(s); structured_verified
    Net cash provided by financing activities was $2.3 billion in the nine months ended June 30, 2026 principally from the $3.0 billion issuance of senior notes and $1.5 billion of term loan borrowings, offset by $1.0 billion of purchases of common stock, $900.0 million of term loan repayments, $360.6 million in cash dividends, and $105.3 million purchases of common stock related to employee tax withholdings.
  11. Geographic Market Commentary · Geographic mixPriority 53
    2 sources (press_release, sec_filing); quote_verified
    On a constant currency basis, International Healthcare Solutions revenue increased by 6.1% and segment operating income increased by 23.1% in the third quarter fiscal 2026 vs prior year third quarter
  12. FX / Currency Headwinds · Currency / FXPriority 51
    quote_verified
    We have exposure to foreign exchange risk primarily with the U.K. Pound Sterling, the Euro, the Turkish Lira, the Brazilian Real, and the Canadian Dollar and we use forward contracts to hedge certain intercompany receivable and payable balances.

Threads by pillar

Revenue & Demand Priority 88 · 6 threads

Costs & Margins Priority 81 · 6 threads

Capital & Balance Sheet Priority 92 · 6 threads

Strategy & Portfolio Priority 76 · 2 threads

Legal, Regulatory & Policy Priority 47 · 3 threads

Guidance & Outlook Priority 80 · 1 thread

Macro & Market Conditions Priority 64 · 4 threads

Unclassified Priority 60 · 1 thread

Expected impact by metric

metricforward netforward grossrealized
revenue+9.5%+9.5%+42.0%
liability-3.8%+4.2%-30.3%
cash-0.8%+0.8%-4.2%
assets+0.5%+0.5%-0.3%
operating_income——+3.6%
net_income——+1.6%